Chairman and CEO
Mr. Elam co-founded AntriaBio - now Rezolute - in October 2012 with Dr. Huh and Dr. Mantripragada, and brings to the company a rich background in management, operations, consulting, finance, and corporate law. He currently serves on the board of directors of Savara Pharmaceuticals in Austin, Texas as well as Aerogen, Inc. in Galway, Ireland.
Mr. Elam was previously CEO of AeroSurgical Limited, a European medical device company, and prior to that, had a very successful career at Nektar Therapeutics (NASDAQ: NKTR). He served as SVP and Head of the Pulmonary Business Unit where he managed a team of over 600 professionals and various partnerships with large pharmaceutical companies. He successfully worked with members of his scientific team at Nektar to spin out Pearl Therapeutics to focus on treatments for asthma and COPD (in 2013 Pearl Therapeutics was acquired by AstraZeneca for $1 billion). In 2008, he negotiated the sale of the pulmonary business unit at Nektar to Novartis for $200 million enterprise value.
Prior to his role at Nektar, Mr. Elam was CFO and co-founder of E2open, (NASDAQ: EOPN), an IT platform company serving the electronics and healthcare industries where, in addition to managing finance and corporate and business development, he established operations in five locations in Asia including Singapore, Kuala Lumpur, Taipei, Tokyo, and Seoul.
In the 1990s, Mr. Elam had a successful career at the venerable law firm of Wilson Sonsini Goodrich & Rosati in Palo Alto, California where he was a partner in the corporate practice. He worked with companies in a variety of industries including healthcare, where his clients ranged from large biotech organizations such as Genentech to small novel therapeutic companies in the US and Europe. Mr. Elam advised clients on a range of matters including debt and equity financings, FDA issues, acquisitions, partnerships and cross-border transactions. He also served clients such as Hewlett Packard and Sun Microsystems and notably, in 1997 he negotiated the sale of Steve Jobs' company, Next, to Apple.
Mr. Elam received his B.A. from Howard University and his J.D. from Harvard Law School.
Vice Chairman and Founder
In addition to his role at Rezolute, Dr. Hoyoung Huh currently serves as the Chairman of Geron Corporation (NASDAQ: GERN) and Chairman of CytomX Therapeutics. Dr. Huh has been involved in the formation, management and financing of more than 20 successful entities across the United States, Europe and Asia. He was previously President & CEO of BiPar Sciences, which was acquired by Sanofi for $500 million in 2009. He also served as Chairman of Epizyme (NASDAQ:EPZM), Chief Operating Officer and board member of Nektar Therapeutics (NASDAQ:NKTR), board member of EOS, which was acquired by Clovis Oncology in 2013, board member of Calibra Medical, which was acquired by J&J in 2012 and board member of Facet Biotech (NASDAQ:FACT), which was acquired by Abbott Laboratories for $722 million in 2010. Dr. Huh was formerly a partner at McKinsey & Company in the healthcare and technology practices. Dr. Huh holds a B.S. in Biochemistry from Dartmouth College, an M.D. from Cornell University Medical College and a Ph.D. in Cell Biology & Genetics from Cornell University/Sloan-Kettering Institute.
Chief Scientific Officer
As the author and inventor of over 70 publications and patents, Dr. Mantripragada is a widely recognized expert in long-acting injectable therapies with demonstrated success in the discovery and development of a number of commercially marketed drugs, including Exparel®, Depocyt® and Xcience®. He designed and developed Locemia Solutions' intranasal glucagon, the first potential needle-free rescue treatment for severe hypoglycemia that was recently acquired by Eli Lilly and Company. Prior to co-founding AntriaBio - now Rezolute - with Mr. Elam & Dr. Huh, Dr. Mantripragada served as Vice President and Head of Research & Development at PR Pharmaceuticals, Inc. Throughout his career, Dr. Mantripragada has served as an advisor to several companies specializing in diabetes, cell based therapies and cardiovascular diseases. His prior roles include Director of Research & Development at Guidant Corporation (now part of Abbott Vascular), as well as Director of Research & Development and Vice President of Scientific Development at SkyePharma (now Pacira Pharmaceuticals). Prior to transitioning to the pharmaceutical industry, Dr. Mantripragada was Assistant Professor of Biochemistry at the University of Virginia School of Medicine. His training includes a Ph.D. in Molecular Biophysics from the Indian Institute of Science and postdoctoral research at the Max Planck Institute for Biophysical Chemistry in Germany.
Ms. Fields has served as the Company-s Controller since October 2012. Prior to joining AntriaBio - now Rezolute - Ms. Fields was an Assurance Director with McGladrey LLP (now RSM US LLP), the fifth largest accounting firm in the US. Ms. Fields is a Certified Public Accountant and received her Bachelor and Master of Accounting from the University of Northern Iowa.
VP, Clinical Development
Prior to joining AntriaBio - now Rezolute - Dr. Roberts directed clinical development at Fibrogen, Inc, where he helped successfully launch the global Phase 3 program and pharmaceutical partnership for a novel oral therapy for anemia associated with kidney disease. From 2007 until 2012 Dr. Roberts held clinical development positions of increasing responsibility at Metabolex, Inc., where he developed novel therapies for metabolic diseases such as diabetes, dyslipidemia, and gout. His program and clinical leadership from IND through clinical proof-of-concept helped secure a global licensing and co-development agreement with a major pharmaceutical partner for a novel diabetes therapy. He is an inventor or author on more than 20 patents and publications in the fields of Endocrinology and Metabolism. Dr. Roberts received his B.S. in biochemistry from the University of California, San Diego and his medical degree Magna Cum Laude from Georgetown University. He completed residency in Internal Medicine and fellowship in Endocrinology at Stanford University, where he also now serves as Adjunct Associate Professor in the Division of Endocrinology.
Prior to joining AntriaBio - now Rezolute - in January 2016, Mr. Deperro spent the past two decades in technical operations leadership roles within large pharma, biotech, generics and in a contract development and manufacturing capacity. A Mechanical Engineer from the University of Notre Dame and former US Army Officer, Mike's early career focused on the implementation of manufacturing and research infrastructure in the US and Ireland for companies including Schering Plough, Merck and Novartis. Transitioning from pharmaceutical engineering to operations management, Mike directed the startup of a generic parenterals business unit, focusing on plant establishment, product development and support of product launch for global markets. As Director of Manufacturing at Alkermes, Mike's manufacturing operation supported global sales of Risperdal® Consta®, the launch of Vivitrol® and delivery of Phase 3 supplies for Bydureon®, all commercialized controlled release formulations utilizing injectable microsphere technologies. These commercial manufacturing operations encompassed polymerization, bulk sterile microsphere manufacture and aseptic fill finish for US and ROW markets. Most recently, as General Manager for GMP Operations at Bend Research, and Vice President of Operations for Agere Pharmaceuticals, Mike led specialized teams charged with the delivery of early phase clinical supplies for complex, poorly soluble molecules in fast-paced multi-client environments. Mike's passion for leadership, integration of complex technologies and a strong belief in positive patient outcomes provide a strong foundation for the development of sustainable operations at Rezolute.
VP, Corporate Development
Prior to joining AntriaBio - now Rezolute - in May 2014, Ms. Liffick served as Vice President in the Healthcare practice of Gerson Lehrman Group, where she spent nearly a decade overseeing key client accounts in New York, Chicago and San Francisco. Ms. Liffick has a proven track record of managing relationships with healthcare institutional investors at hedge funds, mutual funds, private equity firms and venture capital firms. Additionally, she was responsible for developing live and virtual events for GLG's extensive client base at several global endocrinology conferences. Ms. Liffick received her Master of Public Health in Health Policy and Management from Columbia University and Bachelor of Arts in Molecular Cell Biology from University of California Berkeley.